You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 和黃醫藥(0013.HK)大跌超10%續創新低 年度虧損擴大
格隆匯 03-07 10:34
格隆匯3月7日丨和黃醫藥(0013.HK)績後連續2日大跌,現跌超10%,盤中低見30.85港元續創歷史低價,總市值274億港元。公司2021財年全年虧損1.95億美元,虧損同比擴大54.81%,基本每股收益為-0.25美元。分析人士稱,和黃醫藥目前已有3款創新藥獲批上市,分別是索凡替尼、呋喹替尼和賽沃替尼。報吿期研發投入和銷售開支大幅增加,導致公司虧損嚴重。首席財務官鄭澤鋒則指,集團會持續投入研發,去年的研發開支近3億美元,由於很多藥物正在開發,料未來一至兩年對研發的投入會是高峯,相關開支估計會持續擴大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account